|
Group
|
A
|
B
|
%a
|
A
|
B
|
%a
|
|---|
| |
Plasma
| |
Blood
| |
|---|
|
Pharmacokinetic parameters
|
|
Tmax (h)
|
4 ± 3
|
16 ± 9*
|
-
|
4 ± 3
|
14 ± 11
|
-
|
|
Cmax (μg/g)
|
14.1 ± 3.6
|
3.3 ± 1.2**
|
23.4
|
8.5 ± 2.2
|
2.1 ± 0.8**
|
24.7
|
|
AUC(0-12h) (h* μg/g)
|
65.6 ± 6.0
|
21.6 ± 14.0**
|
32.9
|
40.0 ± 4.8
|
13.3 ± 9.1**
|
33.3
|
|
AUC(0-24h) (h* μg/g)
|
98.4 ± 17.2
|
49.9 ± 20.8**
|
50.7
|
61.7 ± 13.1
|
29.8 ± 12.9**
|
48.3
|
|
AUC(0-48h) (h* μg/g)
|
136 ± 28
|
91.0 ± 23.2*
|
66.9
|
88.3 ± 19.0
|
56.9 ± 13.1*
|
64.4
|
|
AUC(0-60h) (h* μg/g)
|
148 ± 31
|
105 ± 25*
|
70.9
|
97.2 ± 20.6
|
67.3 ± 13.8*
|
69.2
|
|
AUC(0-72h) (h* μg/g)
|
157 ± 32
|
116 ± 26
|
73.9
|
105 ± 22
|
76.4 ± 14.2*
|
72.8
|
|
AUCall(0-144h) (h* μg/g)
|
190 ± 38
|
158 ± 32
|
83.2
|
139 ± 25
|
118 ± 16
|
84.9
|
|
Vz (g/kg)
|
7008 ± 2962
|
5629 ± 1946
|
-
|
8860 ± 1848
|
9515 ± 1647
|
-
|
|
Cl (g/h/kg)
|
40.7 ± 5.5
|
49.8 ± 8.3
|
-
|
48.4 ± 7.9
|
47.6 ± 7.3
|
-
|
|
MRTlast (h)
|
35.9 ± 1.8
|
50.2 ± 5.1**
|
-
|
43.6 ± 3.1
|
58.4 ± 5.7**
|
-
|
-
aPercentage of radioactivity remaining in plasma or blood following pre-treatment with formoline L112 compared to the untreated control group
- * P ≤ 0.05, ** P ≤ 0.01
